Naguy, A and Pridmore, S and Alamiri, B, Adjuvant pitolisant in a case with early-onset schizophrenia, Clinical Neuropharmacology ISSN 0362-5664 (2021) [Contribution to Refereed Journal]
Objectives: Early-onset schizophrenia is notorious for poor prognostication and treatment refractoriness. Child/adolescent psychiatric population, by virtue of age, is at a heightened risk for cardiometabolic risk of atypical antipsychotics. Available pharmacological options are, sorely, too limited to mitigate this risk.
Methods: The authors are reporting here on an adolescent case with early-onset schizophrenia who has favorably responded to olanzapine but with problematic weight gain that failed a trial of add-on metformin. A trial of add-on pitolisant was pursued.
Results: Adjunctive pitolisant has successfully helped with the weight issue. Strikingly, there were parallel improvements in both cognitive and negative domains as well.
Conclusions:Add-on pitolisant can be a safe and effective strategy to address antipsychotic-induced metabolic syndrome. Gains might also span negative/cognitive domains. This might open new treatment venues for such complicated clinical scenarios that await replication in larger rigorous studies.
|Item Type:||Contribution to Refereed Journal|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Psychiatry (incl. psychotherapy)|
|Objective Group:||Public health (excl. specific population health)|
|Objective Field:||Mental health|
|UTAS Author:||Pridmore, S (Professor Saxby Pridmore)|
Repository Staff Only: item control page